Last reviewed · How we verify
Infuvite Pediatric (RIBOFLAVIN)
Infuvite Pediatric (Riboflavin) is a small molecule drug developed by HOSPIRA and currently owned by Glaukos. It targets the enzyme flavin reductase (NADPH) and belongs to the drug class of riboflavin (vitamin B2). Infuvite Pediatric is FDA-approved for the prevention of mineral and vitamin deficiencies, with an approval date of 1953. The drug is off-patent, meaning it is no longer protected by active patents. As a result, there are currently no generic manufacturers of the drug.
At a glance
| Generic name | RIBOFLAVIN |
|---|---|
| Sponsor | Glaukos |
| Drug class | Vitamin C [EPC] |
| Target | Flavin reductase (NADPH) |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1953 |
Approved indications
- Mineral Deficiency Prevention
- Mineral deficiency
- Vitamin Deficiency Prevention
- Vitamin deficiency
Common side effects
- Pemphigus
- Systemic lupus erythematosus
- Glossodynia
- Hand deformity
- Arthropathy
- Rheumatoid arthritis
- Alopecia
- Abdominal discomfort
- Wound
- Maternal exposure during pregnancy
- Toxicity to various agents
- Completed suicide
Key clinical trials
- Colon-delivered Riboflavin and Gut Microbiota Composition (NA)
- Mindfulness And Placebo for Pain (MAPP) Study (NA)
- Validation of a Novel Functional Food Designed to Meet the Nutritional Needs of People Living With Parkinson's Disease (NA)
- Chompions! A Treatment Study for Childhood Avoidant/Restrictive Food Intake Disorder (ARFID) (NA)
- Microbiome-Targeted Enhancement of Neurocognition With Probiotics-Riboflavin Combination (NA)
- Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome (PHASE3)
- Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases (PHASE3)
- PRoTECT: Corneal Wavefront Guided PRK + Epi-off CXL vs. PTK+Epi-off CXL in Keratoconus (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infuvite Pediatric CI brief — competitive landscape report
- Infuvite Pediatric updates RSS · CI watch RSS
- Glaukos portfolio CI